1
|
Liu P, Tang L, Kong WH, Zhu ZR, Xiao P, Wang X, Zhou W, Liu MQ. Anti-HIV-1 antibodies based confirmatory results in Wuhan, China, 2012-2018. PLoS One 2020; 15:e0238282. [PMID: 32915788 PMCID: PMC7485867 DOI: 10.1371/journal.pone.0238282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Accepted: 08/13/2020] [Indexed: 11/18/2022] Open
Abstract
The number, intensity and order of emergence of HIV-1 specific antibodies in serum or plasma were associated with the stage of HIV-1 infection. In this study, we retrospectively analyzed the HIV-1 confirmatory results tested by western blot (WB) or recombination immunoblot assay (RIBA) in Wuhan, 2012-2018, to access the profiles of HIV-1 specific antibodies. A total of 14432 HIV-suspected serum or plasma samples collected from local hospitals and other HIV screening laboratories were further screened by two 4th generation enzyme-linked immunosorbent assay (ELISA) kits in our laboratory, of which 11068 specimens (76.69%) had at least one positive ELISA result and thereby were finally confirmed with WB or RIBA. RIBA had identified 652 (81.09%) positive and 13 (1.62%) indeterminate cases from July 1, 2014 to January 7, 2015, while WB had identified 8358 (81.43%) positive and 643 (6.26%) indeterminate cases in the other times during 2012-2018. The indeterminate rate of WB was significant higher than that of RIBA (p<0.001). Although the number of HIV-1 infected subjects increased significantly from 2012 (n = 911) to 2018 (n = 1578), the positive rate of HIV-1 antibodies decreased markedly from 70.08% in 2012 to 58.79% in 2018 (p<0.001). The most commonly observed antibody profile was gp160+gp120+p66+(p55+)p51+gp41+p31+p24+p17+ (4131, 49.43%) for WB-MP and gp160+gp120+gp41+p31+p24+p17+ (382, 58.59%) for RIBA-WANTAI, and the absence of reactivity to three possible serologic markers for recent HIV-1 infection, p31, p66, and p51, increased significantly from 2012 to 2018, with the overall rate of 17.03%, 9.40%, and 15.15%, respectively. The suspected acute HIV-1 infection was also observed to be increased in recent years, with an overall rate of 1.00%. Our results indicated the detection rate had decreased for HIV-1 infection, but increased for suspected recent and acute HIV-1 infection during 2012-2018, reflecting the efforts of intervention among high risk population.
Collapse
Affiliation(s)
- Pan Liu
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Li Tang
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Wen-Hua Kong
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Ze-Rong Zhu
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Peng Xiao
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Xia Wang
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Wang Zhou
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
| | - Man-Qing Liu
- Wuhan Center for Disease Control & Prevention, Wuhan, Hubei, China
- * E-mail:
| |
Collapse
|
2
|
Liu MQ, Zhao M, Kong WH, Tang L, Wang F, Zhu ZR, Wang X, Qiu HY, Zhou DJ, Wang X, Ho WZ, Zhou W. Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway. Oncotarget 2017; 8:22524-22533. [PMID: 28186978 PMCID: PMC5410242 DOI: 10.18632/oncotarget.15121] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Accepted: 01/23/2017] [Indexed: 12/25/2022] Open
Abstract
JAK-STAT signaling pathway has a crucial role in host innate immunity against viral infections, including HIV-1. We therefore examined the impact of HIV-1 infection and combination antiretroviral therapy (cART) on JAK-STAT signaling pathway. Compared to age-matched healthy donors (n = 18), HIV-1-infected subjects (n = 18) prior to cART had significantly lower expression of toll-like receptors (TLR-1/4/6/7/8/9), the IFN regulatory factors (IRF-3/7/9), and the antiviral factors (OAS-1, MxA, A3G, PKR, and Tetherin). Three months’ cART partially restores the impaired functions of JAK-STAT-mediated antiviral immunity. We also found most factors had significantly positive correlations (p < 0.05) between each two factors in JAK-STAT pathway in healthy donors (98.25%, 168/171), but such significant positive associations were only found in small part of HIV-1-infected subjects (43.86%, 75/171), and stably increased during the cART (57.31%, 98/171 after 6 months’ cART). With regard to the restoration of some HIV-1 restriction factors, HIV-1-infected subjects who had CD4+ T cell counts > 350//μl responded better to cART than those with the counts < 350/μl. These findings indicate that the impairment of JAK-STAT pathway may play a role in the immunopathogenesis of HIV-1 disease.
Collapse
Affiliation(s)
- Man-Qing Liu
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Min Zhao
- Wuhan Institute of Dermatology and Venereology, Wuhan 430030, China
| | - Wen-Hua Kong
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Li Tang
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Fang Wang
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Ze-Rong Zhu
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Xia Wang
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Hong-Yan Qiu
- Wuhan Institute of Dermatology and Venereology, Wuhan 430030, China
| | - Dun-Jin Zhou
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| | - Xu Wang
- Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19104, USA
| | - Wen-Zhe Ho
- Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19104, USA
| | - Wang Zhou
- Wuhan Centers for Disease Prevention and Control, Wuhan 430015, China
| |
Collapse
|
3
|
López-Marzo AM, Merkoçi A. Paper-based sensors and assays: a success of the engineering design and the convergence of knowledge areas. LAB ON A CHIP 2016; 16:3150-76. [PMID: 27412239 DOI: 10.1039/c6lc00737f] [Citation(s) in RCA: 124] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
This review shows the recent advances and state of the art in paper-based analytical devices (PADs) through the analysis of their integration with microfluidics and LOC micro- and nanotechnologies, electrochemical/optical detection and electronic devices as the convergence of various knowledge areas. The important role of the paper design/architecture in the improvement of the performance of sensor devices is discussed. The discussion is fundamentally based on μPADs as the new generation of paper-based (bio)sensors. Data about the scientific publication ranking of PADs, illustrating their increase as an experimental research topic in the past years, are supplied. In addition, an analysis of the simultaneous evolution of PADs in academic lab research and industrial commercialization highlighting the parallelism of the technological transfer from academia to industry is displayed. A general overview of the market behaviour, the leading industries in the sector and their commercialized devices is given. Finally, personal opinions of the authors about future perspectives and tendencies in the design and fabrication technology of PADs are disclosed.
Collapse
Affiliation(s)
- Adaris M López-Marzo
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona 08193, Spain.
| | - Arben Merkoçi
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona 08193, Spain. and Institucio Catalana de Recerca i Estudis Avançats (ICREA), Pg. Lluís Companys 23, 08010 Barcelona, Spain
| |
Collapse
|
4
|
Liu MQ, Zhu ZR, Kong WH, Tang L, Peng JS, Wang X, Xu J, Schilling RF, Cai T, Zhou W. High rate of missed HIV infections in individuals with indeterminate or negative HIV western blots based on current HIV testing algorithm in China. J Med Virol 2016; 88:1462-6. [PMID: 26856240 DOI: 10.1002/jmv.24490] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/04/2016] [Indexed: 11/12/2022]
Abstract
It remains unclear if China's current HIV antibody testing algorithm misses a substantial number of HIV infected individuals. Of 196 specimens with indeterminate or negative results on HIV western blot (WB) retrospectively examined by HIV-1 nucleic acid test (NAT), 67.57% (75/111) of indeterminate WB samples, and 16.47% (14/85) of negative WB samples were identified as NAT positive. HIV-1 loads in negative WB samples were significantly higher than those in indeterminate WB samples. Notably, 86.67% (13/15) of samples with negative WB and double positive immunoassay results were NAT positive. The rate of HIV-1 infections missed by China's current HIV testing algorithm is unacceptably high. Thus, China should consider using NAT or integrating fourth generation ELISA into current only antibodies-based HIV confirmation. J. Med. Virol. 88:1462-1466, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Man-Qing Liu
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Ze-Rong Zhu
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Wen-Hua Kong
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Li Tang
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Jin-Song Peng
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Xia Wang
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Jun Xu
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| | - Robert F Schilling
- Department of Social Welfare, Luskin School of Public Affairs, University of California, Los Angeles, California
| | - Thomas Cai
- AIDS Care of China, Nanning, Guangxi, China
| | - Wang Zhou
- Department of Virology, Wuhan Centers for Disease Prevention and Control, Wuhan, China
| |
Collapse
|
5
|
Liu MQ, Zhao M, Kong WH, Peng JS, Wang F, Qiu HY, Zhu ZR, Tang L, Sang M, Wu JG, Ho WZ, Zhou W. Antiretroviral Therapy Fails to Restore Levels of HIV-1 Restriction miRNAs in PBMCs of HIV-1-infected MSM. Medicine (Baltimore) 2015; 94:e2116. [PMID: 26579828 PMCID: PMC4652837 DOI: 10.1097/md.0000000000002116] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
A number of cellular microRNAs (miRNAs) have been identified to have the ability to inhibit HIV-1 replication. In this study, we examined the impact of combination antiretroviral therapy (cART) on the expression of HIV-1 restriction miRNAs in peripheral blood mononuclear cells of HIV-1-infected men who have sex with men (MSM). Compared with male healthy donors, HIV-infected MSM had significantly lower levels of 9 HIV-1 restriction miRNAs. The treatment of HIV-1-infected MSM with cART, however, failed to restore the levels of these miRNAs in peripheral blood mononuclear cells. These observations suggest that the suppression of the cellular restriction miRNAs by HIV-1 may attribute to the virus latency during cART.
Collapse
Affiliation(s)
- Man-Qing Liu
- From the Department of Virology, Wuhan Centers for Disease Prevention & Control (M-QL, W-HK, J-SP, FW, Z-RZ, LT, WZ); Wuhan Institute of Dermatology and Venereology, Wuhan (MZ, H-YQ); Central Laboratory of the Fourth Affiliated Hospital in Xiangyang, College of Basic Medical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan (MS); State Key Laboratory of Virology, Wuhan University, Wuhan, China (J-GW, W-ZH); and Department of Pathology and Laboratory Medicine, Temple University School of Medicine, Philadelphia, PA (W-ZH)
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Nahavandi S, Baratchi S, Soffe R, Tang SY, Nahavandi S, Mitchell A, Khoshmanesh K. Microfluidic platforms for biomarker analysis. LAB ON A CHIP 2014; 14:1496-514. [PMID: 24663505 DOI: 10.1039/c3lc51124c] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Biomarkers have been described as characteristics, most often molecular, that provide information about biological states, whether normal, pathological, or therapeutically modified. They hold great potential to assist diagnosis and prognosis, monitor disease, and assess therapeutic effectiveness. While a few biomarkers are routinely utilised clinically, these only reflect a very small percentage of all biomarkers discovered. Numerous factors contribute to the slow uptake of these new biomarkers, with challenges faced throughout the biomarker development pipeline. Microfluidics offers two important opportunities to the field of biomarkers: firstly, it can address some of these developmental obstacles, and secondly, it can provide the precise and complex platform required to bridge the gap between biomarker research and the biomarker-based analytical device market. Indeed, adoption of microfluidics has provided a new avenue for advancement, promoting clinical utilisation of both biomarkers and their analytical platforms. This review will discuss biomarkers and outline microfluidic platforms developed for biomarker analysis.
Collapse
Affiliation(s)
- Sofia Nahavandi
- Faculty of Medicine, Dentistry, & Health Sciences, The University of Melbourne, VIC 3010, Australia.
| | | | | | | | | | | | | |
Collapse
|